Quality of Online Information on Multiple Myeloma Available for Laypersons
- PMID: 35877218
- PMCID: PMC9324394
- DOI: 10.3390/curroncol29070358
Quality of Online Information on Multiple Myeloma Available for Laypersons
Abstract
Online information can increase patients' competence and engagement. However, there are concerns regarding invalid information. Overall, 300 websites and 50 YouTube videos on multiple myeloma (MM) were evaluated. The websites did not differ between the search engines or search ranks. The median time since the last update was 9 months. The 63 unique websites showed a poor general quality (median JAMA score 2 of 4, only 18% with a valid HON certificate). The patient- (user-) focused quality was medium to poor (median sum DISCERN score 41 out of 80 points). The overall reading level was difficult requiring at least a 12th US school grade. The content level was low (median 24 out of 73 points). Sixteen percent contained misleading/wrong facts. Websites provided by foundation/advocacies showed a significantly higher general and patient- (user-) focused quality. For videos, the median time since upload was 18 months. Judged by the HON foundation score ~80% of videos showed a medium general quality. The patient- (user-) focused quality was medium to poor (median sum DISCERN score 43 points). The content level was very low (median 8 points). MM relevant websites and videos showed a medium to low general, patient- (user-) focused and content quality. Therefore, incorporation of quality indices and regular review is warranted.
Keywords: multiple myeloma; online health information; patient education.
Conflict of interest statement
The first author and all co-authors confirm that there are no potential conflicts of interest to disclose, except the following: Sandra Sauer: travel grants or honoraria for presentations for Celgene, BMS, Janssen, Takeda and Amgen; Karin Jordan: advisory board and/or honoraria for presentations for MSD, Amgen, Hexal, Riemser, Helsinn, Voluntis, Pfizer, Pomme-med, art-tempi, Astra Zeneca, Takeda, Mundipharma, and OnkoUpdate; Hartmut Goldschmidt: Grants and/or provision of Investigational Medicinal Product: Amgen, BMS, Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Sanofi. Research Support: Amgen, BMS, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp and Dohme (MSD), Sanofi, Mundipharma GmbH, Takeda, Novartis. Advisory Boards: Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda. Honoraria: Amgen, BMS, Celgene, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi; Carsten Müller-Tidow: research support and support for clinical trials from multiple pharmaceutical companies; Katharina Kriegsmann: research support from BMS, Celgene, Sanofi.
Figures
References
-
- Eutostat 53% of EU Citizens Sought Health Information Online. 2020. [(accessed on 15 May 2021)]. Available online: https://ec.europa.eu/eurostat/de/web/products-eurostat-news/-/ddn-202003....
-
- Iverson S.A., Howard K.B., Penney B.K. Impact of internet use on health-related behaviors and the patient-physician relationship: A survey-based study and review. J. Am. Osteopath. Assoc. 2008;108:699–711. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
